Quick Summary
India has approved Takeda’s QDENGA (TAK-003) as the country’s first licensed dengue vaccine. The vaccine protects against all four dengue virus serotypes, is given in two doses three months apart, and can be administered regardless of prior dengue infection. The approval is expected to strengthen dengue prevention alongside mosquito control measures.
Takeda’s QDENGA Becomes India’s First Approved Dengue Vaccine in India
India has granted marketing authorization to Takeda’s QDENGA (TAK-003), making it the first approved dengue vaccine in India. This landmark approval represents a major advancement in the country’s fight against dengue, a mosquito-borne viral disease that affects lakhs of people every year.
The Takeda QDENGA Dengue Vaccine India approval introduces a vaccine that provides protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Unlike some earlier vaccines, QDENGA does not require pre-vaccination screening and can be administered regardless of previous dengue infection.
Overview
| Particular | Details |
|---|---|
| Vaccine Name | QDENGA (TAK-003) |
| Developed By | Takeda Pharmaceutical Company |
| Approval Status | Marketing Authorization in India |
| Vaccine Type | Live Attenuated Tetravalent Dengue Vaccine |
| Target Disease | Dengue Fever |
| Eligible Age Group | 4–60 Years |
| Number of Doses | Two |
| Dose Interval | Three Months Apart |
| Route of Administration | 0.5 mL Subcutaneous Injection |
| Prior Dengue Infection Required | No |
What is QDENGA?
QDENGA (TAK-003) is a live attenuated tetravalent dengue vaccine developed by Takeda Pharmaceutical Company. It is designed to provide protection against all four dengue virus serotypes, helping reduce the risk of symptomatic dengue infection and dengue-related hospitalization.
One of its major advantages is that it can be administered regardless of whether a person has previously been infected with dengue, eliminating the need for pre-vaccination blood testing.
Eligibility
| Criteria | Details |
|---|---|
| Age Group | 4–60 Years |
| Previous Dengue Infection | Not Required |
| Pre-Vaccination Screening | Not Required |
Eligible individuals should receive the vaccine based on the advice of healthcare professionals and applicable public health recommendations.
Dosage Schedule
| Dose | Timing |
|---|---|
| First Dose | Day 0 |
| Second Dose | After 3 Months |
QDENGA is administered as a 0.5 mL subcutaneous injection in a two-dose schedule.
Clinical Effectiveness
Clinical studies have demonstrated strong protection against dengue infection and severe disease.
| Outcome | Result |
|---|---|
| Efficacy Against Virologically Confirmed Dengue | 80.2% one year after the second dose |
| Protection Against Dengue-Related Hospitalization | 90.4% after 18 months |
| Long-Term Protection | Up to seven years (TIDES Study) |
TIDES Phase III Study
The TIDES Phase III clinical trial evaluated the long-term safety and effectiveness of QDENGA.
Key Findings
- Protection against all four dengue virus serotypes
- Demonstrated efficacy for up to seven years
- Sustained immune response
- Reduced risk of severe dengue
- Reduced dengue-related hospitalization
The long-term findings support the vaccine’s role in strengthening dengue prevention strategies.
Key Benefits of QDENGA
- Protects against all four dengue virus serotypes
- India’s first approved dengue vaccine
- Two-dose vaccination schedule
- No prior dengue infection required
- No pre-vaccination blood testing needed
- Demonstrated long-term protection
- Helps reduce severe dengue and hospitalization
Why is This Approval Important?
Dengue continues to be one of India’s most significant mosquito-borne diseases, causing seasonal outbreaks across many states.
The approval of QDENGA provides an additional preventive tool alongside:
- Mosquito control programs
- Public awareness campaigns
- Early diagnosis
- Timely medical treatment
Vaccination is expected to contribute to reducing severe dengue cases and hospitalization while complementing existing public health measures.
Who Can Receive the Vaccine?
QDENGA is approved for:
- Individuals aged 4–60 years
- People with or without previous dengue infection
- Eligible recipients as advised by healthcare professionals
Key Highlights
- India’s first approved dengue vaccine
- Developed by Takeda Pharmaceutical Company
- Protects against all four dengue virus serotypes
- Two-dose vaccination schedule
- No prior dengue testing required
- Up to seven years of demonstrated protection
- Approved in multiple countries before India
Important Information
| Particular | Details |
|---|---|
| Official Approval | Marketing Authorization Granted |
| Vaccine Name | QDENGA (TAK-003) |
| Manufacturer | Takeda Pharmaceutical Company |
| Official Notification | Available through the company and regulatory announcements |
Important Links
| Description | Link |
|---|---|
| Takeda Official Website | https://www.takeda.com |
| Official India Announcement | Refer to Takeda’s official India communication |
| Product Information | Official Takeda resources |
Internal Linking Suggestions (GDC Classes)
You can internally link this article with:
- Dengue Fever Notes
- Vaccine Classification
- Immunization Schedule
- Pharmacology Notes
- Public Health Pharmacy
- Communicable Diseases
- GPAT Pharmacology Notes
- Pharmacy Current Affairs
Conclusion
The approval of Takeda’s QDENGA marks a historic milestone in India’s dengue prevention efforts. As the country’s first approved dengue vaccine, it offers broad protection against all four dengue virus serotypes through a simple two-dose schedule without requiring prior dengue testing. Supported by long-term clinical evidence from the TIDES Phase III study, QDENGA has the potential to reduce symptomatic dengue, severe disease, and hospitalization. Combined with mosquito control and public health initiatives, this approval represents a significant step toward strengthening India’s response to dengue.
Frequently Asked Questions (FAQs)
Q1. What is QDENGA?
QDENGA is a live attenuated tetravalent vaccine developed by Takeda for the prevention of dengue.
Q2. Is QDENGA the first approved dengue vaccine in India?
Yes. QDENGA is the first dengue vaccine to receive marketing authorization in India.
Q3. How many doses are required?
Two doses administered three months apart.
Q4. Is previous dengue infection required before vaccination?
No. QDENGA can be administered regardless of prior dengue exposure.
Q5. Which age group is eligible?
Individuals aged 4–60 years.
Q6. What did the TIDES study demonstrate?
The TIDES Phase III study demonstrated protection against all four dengue virus serotypes with follow-up showing protection lasting up to seven years.
Q7. Does QDENGA protect against all dengue virus serotypes?
Yes. It is designed to protect against DENV-1, DENV-2, DENV-3, and DENV-4.
Q8. Does vaccination replace mosquito control?
No. Vaccination should complement mosquito control measures, public awareness, and timely medical care.
Recommended Products
